Springer Protocols: Abstract: Immune Properties of Mesenchymal Stem Cells

Immune Properties of Mesenchymal Stem Cells

By: Panagiota A. Sotiropoulou³, Michael Papamichail³

Abstract

Full Text

Download PDF (391K)

Mesenchymal stem cells (MSCs) are multipotent progenitor cells isolated by various relatively easily accessible tissues, such as bone marrow and cord blood. MSCs gained attention because of their ease for in vitro expansion together with their multilineage potential. More recently, in vitro and in vivo immunosuppressive properties have been ascribed to them, as they are able to modulate the function of all major immune cell populations, thus impeding immune responses. The underlying mechanisms of their differentiation and function are not thoroughly understood, but still they represent important candidates for tissue regeneration and manipulation of the immune response in graft rejection, graft versus host disease, and autoimmune disorders. Characteristics and immunogenic profile of MSCs, their interface with immune system and their potential use as immunosuppressive elements in cellular therapeutic protocols are reviewed in this chapter.

Affiliation(s): (3) Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Athens, Greece

Book Title: Stem Cell Assays

Series: Methods in Molecular Biology | Volume: 407 | Pub. Date: Aug-10-2007 | Page Range: 225-243 | DOI: 10.1007/978-1-59745-536-7_16

Subject: Cell Biology

Key Words: Mesenchymal stem cells - Immune system - Immune suppression - GVHD - Autoimmunity - Cancer

References

Download References

1.	Conheim, J. (1867) Ueber Entzundung und Eiterung. Pathol. Anat. Physiol. Klin. Med. 40, 1–79.

2.	Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F. and Keiliss-Borok, I. V. (1974) Stromal cells responsible for transferring the micro- environment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17: 331–340.

3.	Deng, W., Obrocka, M., Fischer, I. and Prockop, D. J. (2001) In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP. Biochem. Biophys. Res. Commun. 282: 148–152.

4.	Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J. and Kessler, P. D. (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93–98.

5.	Lee, K. D., Kuo, T. K., Whang-Peng, J., Chung, Y. F., Lin, C. T., Chou, S. H., Chen, J. R., Chen, Y. P. and Lee, O. K. (2004) In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 40 1275–1284.

6.	Dezava, M., Ishikawa, H., Itokazu, Y., Yoshihara, T., Hoshino, M., Takeda, S., Ide, C. and Nabeshima, Y. (2005) Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309, 314–317.

7.	Kuznetsov, S. A., Mankani, M. H., Gronthos, S., Satomura, K., Bianco, P. and Gehron-Robey, P. (2001) Circulating skeletal stem cells. J. Cell Biol. 153: 1133–1139.

8.	Wagner, W., Wein, F., Seckinger, A., Frankhauser, M., Wirkner, U., Krause, U., Blake, J., Schwager, C., Eckstein, V., Ansorge, W. and Ho, A. D. (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp. Hematol. 33: 1402–1416.

9.	Horwitz, E. M., Le Blanc, K., Dominici, M., Mueller, I, Slaper-Cortenbach, I., Marini, F. C., Deans, R. J., Krause, D. S. and Keating A. (2005) Clarification of the nomenclature for MSC. The International Society for Cellular Therapy position statement. Cytotherapy 7, 393–395.

10.	Haynesworth, S. E., Baber, M. A. and Caplan, A. I. (1992) Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal Abs. Bone 13: 69–80.

11.	Barry, F., Boynton, R., Murphy, M., Haynesworth, S. and Zaia, J. (2001) The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 289: 519–524.

12.	Cognet, P. A. and Minguell, J. J. (1999) Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J. Cell. Physiol. 181: 67–73.

13.	Majumdar, M. K., Keane-Moore, M., Buyaner, D., Hardy, W. B., Moorman, M. A., McIntosh K. R. and Mosca, J. D. (2002) Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 10, 228–241.

14.	Wynn, R. F., Hart, C. A., Corradi-Perini, C., O’Neil, L., Evans, C. A., Wraith, J. E., Fairbairn, L. J. and Bellantuono, I. (2004) A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104: 2643–2645.

15.	Le Blanc, K. (2003) Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5: 485–489.

16.	Potian, J. A., Aviv, H., Ponzio, N. M., Harrison J. S. and Rameshwar P. (2003) Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigen and recall antigens. J. Immunol. 171, 3426–3434.

17.	Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor. R., Simpson, E. and Dazzi, F. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722–3729.

18.	Stagg, J., Pommey, S., Eliopoulos, N. and Galipeau J. (2006) Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107, 2570–2577.

19.	Bruder, S. P., Jaiswal, N. and Haynesworth, S. E. (1997) Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J. Cell. Biochem. 64, 278–294.

20.	Haynesworth, S. E., Baber, M. A. and Caplan, A. I. (1996) Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1α. J. Cell. Physiol. 166: 585–592.

21.	Majumdar, M. K., Thiede M. A., Mosca, J. D., Moorman. M. and Gerson, S. L. (1998) Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J. Cell. Physiol. 176: 57–66.

22.	Kim, D. H., Yoo, K. H., Choi, K. S., Choi, J., Choi, S. Y., Yang S. E., Yang, Y. S., Im, H. J., Kim, K. H., Jung, H. L., Sung, K. W. and Koo, H. H. (2005) Gene expression profile of cytokine and growth factor during differentiation of bone marrow-derived mesenchymal stem cell. Cytokine 31: 119–126.

23.	Beyth, S., Borovsky, Z., Mevorach, D., Liebergall, M., Gazit, Z., Aslan, H., Galun, E. and Rachmilewitz, J. (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214–2219.

24.	Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S. and Gianni, A. M. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838–3843.

25.	Klyushnekova, E., Mosca, J. D., Zernetkina, V., Majumdar, M. K., Beggs, K. J., Simonetti, D. W., Deans, R. J. and McIntosh, K. R. (2005) T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12: 47–57.

26.	Rasmusson, I., Rindgen, O., Sundberg, B. and Le Blanc, K. (2005) Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305: 33–41.

27.	Meisel, R., Zibert, A., Laryea, M., Gobel, U., Daubener, W. and Dilloo, D. (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine-2, 3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619–4621.

28.	Plumas, J., Chaperot, L., Richard, M. J., Molens, J. P., Bensa, J. C. and Favrot, M. C. (2005) Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19: 1597–1604.

29.	Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A. and Hoffman, R. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30: 42–48.

30.	Tse, W. T., Pendleton, J. D., Beyer, W. M,. Egalka, M. C. and Gionan, E. C. (2003) Suppression of allogeneic T-cell proliferation by human bone marrow stromal cells: implications in transplantation. Transplantation 75: 389–397.

31.	Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noel, D. and Jorgensen, C. (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837–3844.

32.	Rasmusson, I., Rindgen, O., Sundberg, B. and Le Blanc, K. (2003) Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 27: 1208–1213.

33.	Le Blanc, K., Tammik, L., Sundberg, B., Haynesworth, S. E. and Ringden, O. (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57: 11–20.

34.	Le Blanc, K., Rasmusson, I., Gotherstrom, C., Seidel, C., Sundberg, B., Sundin, M., Rosendahl, K., Tammik, C. and Ringden, O. (2004) Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand. J. Immunol. 60: 307–315.

35.	Aggarwal, S. and Pittenger, M. F. (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815–1822.

36.	Groh, M. E., Maitra, B., Szekely, E. and Koc, O. (2005) Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33, 928–934.

37.	Augello, A., Tasso, R., Negrini, S. M., Amateis, A., Indiveri, F., Cancedda, R. and Pannesi, G. (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482–1490.

38.	Maccario, R., Podesta, M., Moretta, A., Cometa, A., Comoli, P., Montagna, D., Daudt, L., Idatici, A., Piaggio, G., Pozzi, S., Frassoni, F. and Locatelli, F. (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4⁺ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90: 516–525.

39.	Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W. F. and Dazzi, F. (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105: 2821–2827.

40.	Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., Santarlasci, V., Mazzinghi, B., Pizzolo, G., Vinante, F., Romagnani, P., Maggi, E., Romagnani, S. and Annunziato, F. (2006) Role of IFN-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386–398.

41.	Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B. and Palucka, K. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767–811.

42.	Rutella, S., Danese, S. and Leone, G. (2006) Tolerogenic dendritic cells. Cytokine modulation comes of age. Blood 108, 1435–1440.

43.	Steinman, R. M., Pack, M. and Inaba, K. (1997) Dendritic cells in the T-cell areas of lymphoid organs. Immunol. Rev. 156, 25–37.

44.	Zhang, W., Ge, W., Li, C., You, S., Liao, L., Han, Q., Deng, W. and Zhao, R. C. H. (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13, 263–271.

45.	Jiang, X. X., Zhang, Y., Liu, B., Zhang, S. X., Wu, Y., Yu, X. D. and Mao, N. (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120–4126.

46.	Chan, J. L., Tang, K. C., Patel, A. P., Bonilla, L. M., Pierobon, N., Ponzio, N. M. and Rameshwar, P. (2006) Antigen presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 107, 4817–4824.

47.	Ollila, J. and Vihinen, M. (2005) B cells. Int. J. Biochem. Cell Biol. 37: 518–523.

48.	Deng, W., Han, Q., Liao, L., You, S., Deng, H. and Zhao, R. C. H. (2005) Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol. 24: 458–463.

49.	Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V. and Ucceli, A. (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367–372.

50.	Papamichail, M., Perez, S. A., Gritzapis, A. D. and Baxevanis, C. N. (2004) Natural killer lymphocytes: biology, development, and function. Cancer Immunol. Immunother. 53: 176–186.

51.	Poggi, A., Prevosto, C., Massaro, A. M., Negrini, S., Urbani, S., Pierri, I., Saccardi, R., Gobbi, M. and Zocchi, M. R. (2005) Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. 175: 6352–6360.

52.	Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N. and Papamichail. M (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24: 74–85.

53.	Spaggiari, G. M., Capobianco, A., Beccheti, S., Mingari, M. C. and Moretta, L. (2006) Mesenchymal stem cell-natural killer cell interactions; evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484–1490.

54.	Le Blanc, K., Tammik, C., Rosendahl, K,. Zetterberg, E. and Ringden, O. (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31: 890–896.

55.	Maitra, B., Szekely, E., Gjini, K., Laughlin, M. J., Dennis, J., Haynesworth, S. E. and Koc, O. N. (2004) Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33, 597–604.

56.	Liu, H., Kemeny, D. M., Heng, B. C., Ouyang, H. W., Melendez, A. J. and Cao, T. (2006) The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J. Immunol. 176: 2864–2871.

57.	Horwitz, E. M., Gordon, P. L., Koo, W. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L. and Hofmann, T. (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc. Natl. Acad. Sci. U.S.A. 99: 8932–8937.

58.	Koc, O. N., Day, J., Nieder, M., Gerson, S. L., Lazarus, H. M. and Krivit, W. (2002) Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 30, 215–222.

59.	Saito, T., Kuang, J. Q., Bittira, B., Al-Khaldi, A. and Chiu, R. C. (2002) Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Am. Thorac. Surg. 74: 19–24.

60.	Devine, S. M., Cobbs, C., Jennings, M., Bartholomew, A. and Hoffman, R. (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 101: 2999–3001.

61.	Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., Uzunel, M. and Ringden, O. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439–1441.

62.	Lazarus, H. M., Koc, O. N., Devine, S. M., Curtin, P., Maziarz, R.T., Holland, H. K., Shpall, E. J., McCarthy, P., Atkinson, K., Cooper, B. W., Gerson, S. L., Laughlin, M. J., Loberiza, F. R. Jr., Moseley, A. B. and Bacigalupo, A. (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood marrow Transplant. 11: 389–398.

63.	Rasulov, M. F., Vasil’chenkov, A. V., Onishchenko, N. A., Krasheninnikov, M. E., Kravchenko, V. I., Gorshenin, T. L., Pidtsan, R. E. and Potapov, I. V. (2005) First experience in the use of bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. Bull. Exp. Biol. Med. 1, 141–144.

64.	Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S. and Galipeau, J. (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II- mismatched recipient mice. Blood 106: 4057–4065.

65.	Nauta, A. J., Westerhuis, G., Kruisselbrink, A. B., Lurvink, E. G., Willemze, R. and Fibbe, W. E. (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 108: 2114–2120.

66.	Grinnemo, K. H., Mansson, A., Dellgren, G., Klingberg, D., Wardell, E., Drvota, V., Tammik, C., Holgersson, J., Ringden, O., Sylven, C. and Le Blanc, K. (2004) Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infracted rat myocardium. J. Thorac. Cardiovasc. Surg. 127: 1293–1300.

67.	Miura, M., Miura, Y., Padila-Nash, H. M., Molinolo, A. A., Fu, B., Patel, V., Seo, B. M., Sonoyama, W., Zheng, J. J., Baker, C. C., Chen, W., Ried, T. and Shi, S. (2006) Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24: 1095–1103.

68.	Chung, N. G., Jeong, D. C., Park, S. J., Choi, B. O., Cho, B., Kim, H. K., Chun, C. S., Won, J. H. and Ham, C. W. (2004) Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int. J. Hematol. 80: 370–376.

69.	Kim, D. W., Chung, Y.J., Kim, T. G., Kim, Y. L. and Oh, I. H. (2004) Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood 103, 1941–1948.

70.	Lee, S. T., Jang, J. H., Cheong, J. W., Kim, J. S., Meamg, H. Y., Hahn, J. S., Ko, Y. W. and Min, Y. H. (2002) Treatment of high-risk acute myelogenous leukemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched leukocyte antigen haplotype. Br. J. Haematol. 118, 1128–1131.

71.	Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, E., Giunti, D., Ceravolo, A., Cazzanti, F., Frassoni, F., Mancardi, G. and Ucceli, A. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood 106: 1755–1761.

72.	Zhang, J., Li, Y., Chen, J., Cui, Y., Lu, M., Elias, S. B., Mitchell, J. B., Hammill, L., Vanguri, P. and Chopp, M. (2005) Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp. Neurol. 195, 16–26.

73.	Ishida, T., Inaba, M., Hisha, H., Sugiura, K., Adachi, Y., Nagata, N., Ogawa, R., Good, R. A. and Ikehara, S. (1994) Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J. Immunol. 152: 3119–3127.

74.	Djouad, F., Fritz, V., Apparailly, F., Louis-Plence, P., Bony, C., Sany, J., Jorgensen, C. and Noel, D. (2005) Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor αin collagen-induced arthritis. Arthritis Rheum. 52: 1595–1603.

75.	Hung, S.-C., Deng, W.-P., Yang, W. K., Liu, R.-S., Lee, C.-C., Su, T.-C., Lin, R.-J., Yang, D.-M., Chang, C.-W., Chen, W.-H., Wei, H.-J. and Gelovani, J. G. (2005) Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development m